Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ drug therapy
Combined Modality Therapy
Cystadenocarcinoma, Serous
/ drug therapy
Cytoreduction Surgical Procedures
/ adverse effects
Epinephrine
Humans
Hyperthermia, Induced
Ovarian Neoplasms
/ drug therapy
Peritoneal Neoplasms
/ drug therapy
Prospective Studies
Retrospective Studies
Survival Rate
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
14
05
2021
accepted:
30
11
2021
pubmed:
8
1
2022
medline:
12
4
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Ovarian cancer (OC) is the most lethal gynecological cancer. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy appears to increase survival, and normothermic intraperitoneal chemotherapy (IPC) could improve overall survival (OS). Furthermore, intraperitoneal epinephrine could decrease the toxicity of chemotherapy by decreasing the systemic absorption of chemotherapy. The goal of this study was to assess the effects of CRS and IPC with intraperitoneal epinephrine, as first-line therapy, on the survival of patients with serous epithelial OC (EOC) with peritoneal metastases. A prospective monocentric database was retrospectively searched for all patients with advanced serous EOC treated by interval or consolidative CRS plus IPC with intraperitoneal epinephrine after neoadjuvant chemotherapy. OS and disease-free survival (DFS), postoperative complications, and prognostic factors were analyzed. From January 2003 to December 2017, 124 patients with serous EOC were treated with interval (n = 58) or consolidative (n = 66) complete CRS plus IPC with intraperitoneal epinephrine. The median follow-up was 77.8 months, the median OS was 60.8 months, and the median DFS was 21.2 months. In our multivariate analysis, a higher Peritoneal Cancer Index (PCI) and positive lymph node status resulted in worse OS, while higher World Health Organization score, higher PCI score, and positive lymph node status were risk factors for worse DFS. Grade 3 or higher surgical morbidity occurred in 27.42% of cases; only 3.2% had grade 3 renal toxicity and mortality was 0.8%. CRS and IPC with intraperitoneal epinephrine in stage III EOC offer good OS and DFS with acceptable morbidity and mortality rates.
Identifiants
pubmed: 34994906
doi: 10.1245/s10434-021-11211-7
pii: 10.1245/s10434-021-11211-7
doi:
Substances chimiques
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3322-3334Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.
pubmed: 17237035
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
pubmed: 21296855
pmcid: 21296855
Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188–97.
pubmed: 27065709
pmcid: 4818619
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371–82.
pubmed: 19793610
Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637–45.
pubmed: 19701772
Leitao MM, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol. 2009;36(2):106–11.
pubmed: 19332245
Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park). 2013;27(4):288–94.
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.
pubmed: 15590954
Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71(3):431–6.
pubmed: 9887245
Vergote I, Amant F, Ehlen T. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.
pubmed: 20818904
Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 15 Aug 2012 [cited 7 Jun 2020]. https://doi.org/10.1002/14651858.CD005343.pub3 .
Kang S, Nam B-H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315–20.
pubmed: 19517192
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6.
pubmed: 16875720
Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950–5.
pubmed: 8960474
Armstrong DK, Huang HQ, Copeland LJ. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.
pubmed: 16394300
Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.
pubmed: 11181662
Hess LM, Benham-Hutchins M, Herzog TJ, Hsu C-H, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. 2007;17(3):561–70.
pubmed: 17504373
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 12 Jan 2016 [cited 17 Oct 2020]. https://doi.org/10.1002/14651858.CD005340.pub4 .
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–6.
pubmed: 25800756
pmcid: 4404424
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–89.
pubmed: 26453145
Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5.
pubmed: 25391263
Di Giorgio A, De Iaco P, De Simone M, Garofalo A, Scambia G, Pinna AD, et al. Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases. Ann Surg Oncol. 2017;24(4):914–22.
pubmed: 27896512
Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43.
pubmed: 24209430
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.
pubmed: 29342393
Pili-Floury S, Royer B, Bartholin F, Crumiere N, Combe M, Chalopin J-M, et al. Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):199–203.
pubmed: 21306815
Guardiola E, Chauffert B, Delroeux D, Royer B, Heyd B, Combe M, et al. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anti Cancer Drugs. 2010;21(3):320–5.
pubmed: 20032778
Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133(3):401–4.
pubmed: 24878391
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Springer US; 1996. p. 259–74 [cited 9 Oct 2020]. (Freireich EJ [ed]. Cancer Treatment and Research. Vol. 82). https://doi.org/10.1007/978-1-4613-1247-5_23 .
National Cancer Institute. NIH, DHHS, 2009 NIH Publication # 09-7473. Common terminology criteria for adverse events. Volume 4. National Cancer Institute.
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
pubmed: 15273542
pmcid: 15273542
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.
pubmed: 7826158
pmcid: 1234492
Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti Cancer Drugs. 2005;16(9):1009–16.
pubmed: 16162978
Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, et al. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol. 2008;61(3):415–21.
pubmed: 17503047
Favoulet P, Magnin G, Guilland JC, Beltramo JL, Osmak L, Benoit L, et al. Pre-clinical study of the epinephrine–cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur J Surg Oncol. 2001;27(1):59–64.
pubmed: 11237494
Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15(2):542–6.
pubmed: 17929098
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.
Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. ISBN 3-900051-07-0, 2012.
Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, Asencio JM, Alvarez de Sierra P, Atahualpa Arenas F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol. 2013;39(10):1109–15.
pubmed: 23870278
Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1716–21.
pubmed: 25145504
El Halabi H, Gushchin V, Francis J, Athas N, MacDonald R, Nieroda C, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–4.
pubmed: 21701929
Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241(2):300–8.
pubmed: 15650641
pmcid: 1356916
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.
pubmed: 19189349
Aslan K, Meydanli MM, Akilli H, Durmuş Y, Gökçü M, Kayıkçıoğlu F, et al. Does lymph node ratio have any prognostic significance in maximally cytoreduced node-positive low-grade serous ovarian carcinoma? Arch Gynecol Obstet. 2020;302(1):183–90.
pubmed: 32409929
Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351(24):2544–6.
pubmed: 15590959
Sun J-H, Ji Z-H, Yu Y, Wu H-T, Huang C-Q, Zhang Q, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database. Transl Oncol. 2016;9(2):130–8.
pubmed: 27084429
pmcid: 4833965
Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215–20.
pubmed: 21665254
Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011;202(4):481–6.
pubmed: 21474115
Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol. 2010;3(3):111–7.
pubmed: 21364862
pmcid: 3046749
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.
pubmed: 19395008
Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract. 2012;2012:1–12.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.
Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, Képénékian V, Bakrin N, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperth. 2018;34(5):532–7.
Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard A-C, Bakrin N, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796–803.
pubmed: 27110915
Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, et al. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol. 2009;7(1):14.
pubmed: 19203351
pmcid: 2644300
Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo J-L, Bichat F, et al. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am. 2003;12(3):835–48.
pubmed: 14567035
Duvillard C, Benoit L, Moretto P, Beltramo JL, Brunet-Lecomte P, Correia M, et al. Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors. Int J Cancer. 1999;81(5):779–84.
pubmed: 10328233
Facy O, Radais F, Ladoire S, Delroeux D, Tixier H, Ghiringhelli F, et al. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis. J Exp Clin Cancer Res. 2011;30(1):4.
pubmed: 21214912
pmcid: 3024948
Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland J-C, et al. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anti Cancer Drugs. 2006;17(10):1211–7.
pubmed: 17075321
Royer B, Kalbacher E, Onteniente S, Jullien V, Montange D, Piedoux S, et al. Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study. Br J Cancer 2012;106(3):460–7.
doi: 10.1038/bjc.2011.557
pubmed: 22173671